When.com Web Search

  1. Ads

    related to: xarelto versus eliquis bleeding risk rating

Search results

  1. Results From The WOW.Com Content Network
  2. Direct factor Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

    Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]

  3. Rivaroxaban - Wikipedia

    en.wikipedia.org/wiki/Rivaroxaban

    Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [8]

  4. Apixaban - Wikipedia

    en.wikipedia.org/wiki/Apixaban

    Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.

  5. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of ...

    www.aol.com/news/2013-01-02-us-fda-approves...

    U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...

  6. Discovery and development of direct Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4]

  7. Antiplatelet drug - Wikipedia

    en.wikipedia.org/wiki/Antiplatelet_drug

    A decrease in antiplatelet effect would reduce the risk of bleeding, but increase the thromboembolic risk. [3] Drug toxicity may increase when multiple antiplatelet drugs are used. Gastrointestinal bleeding is a common adverse event seen in many patients.

  8. CHA2DS2–VASc score - Wikipedia

    en.wikipedia.org/wiki/CHA2DS2–VASc_score

    This can be done using validated bleeding risk scores, such as the HEMORR 2 HAGES or HAS-BLED scores. [33] The HAS-BLED score is recommended in guidelines, to identify the high risk patient for regular review and followup and to address the reversible risk factors for bleeding (e.g. uncontrolled hypertension, labile INRS, excess alcohol use or ...

  9. Critical Atlantic Ocean current system is showing early signs ...

    www.aol.com/news/crucial-ocean-current-system...

    A crucial system of ocean currents may already be on course to collapse with devastating implications for sea level rise global weather — leading temperatures to plunge dramatically in some ...